PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Gilbert C FAURE's insight:
Abstract
Flow cytometry is an essential tool for dissecting the functional complexity of hematopoiesis. We used single-cell "mass cytometry" to examine healthy human bone marrow, measuring 34 parameters simultaneously in single cells (binding of 31 antibodies, viability, DNA content, and relative cell size). The signaling behavior of cell subsets spanning a defined hematopoietic hierarchy was monitored with 18 simultaneous markers of functional signaling states perturbed by a set of ex vivo stimuli and inhibitors. The data set allowed for an algorithmically driven assembly of related cell types defined by surface antigen expression, providing a superimposable map of cell signaling responses in combination with drug inhibition. Visualized in this manner, the analysis revealed previously unappreciated instances of both precise signaling responses that were bounded within conventionally defined cell subsets and more continuous phosphorylation responses that crossed cell population boundaries in unexpected manners yet tracked closely with cellular phenotype. Collectively, such single-cell analyses provide system-wide views of immune signaling in healthy human hematopoiesis, against which drug action and disease can be compared for mechanistic studies and pharmacologic intervention.
Cell plasticity is a crucial trait for cancer progression towards metastasis and treatment resistance. Research efforts from the past 20–30 years have revealed that the dynamic flux of the epithelial–mesenchymal transition (EMT) programme is one of the major underlying processes enabling cancer cell plasticity and greatly facilitates these major causes of cancer mortality. The spectrum of evidence ranges from extensive data from cell line and animal model studies across multiple cancer types through a rapidly expanding body of work demonstrating associations between EMT biomarkers and disease progression and mortality in patients. EMT is also implicated in resistance to most of the major treatment modalities, yet our efforts to harness this knowledge to improve therapeutic outcomes are currently in their early stages. In this Review, we describe clinical evidence supporting a role of EMT and the associated epithelial–mesenchymal plasticity in various stages of cancer in patients and discuss the subsequent clinical opportunities and challenges associated with attempts to implement this knowledge as novel therapies or clinical management approaches. Despite several decades of research that has revealed roles in the development and progression of many solid tumours, clinical translation of research targeting epithelial–mesenchymal transition (EMT) has thus far been limited. In this Review, the authors provide a summary of the role of EMT in cancer development and progression in the context of this lack of clinical translation, summarize the current status of direct or indirect EMT-modulating agents in clinical development, and highlight the major barriers to the development of EMT-related clinical interventions.
Cellular interactions are of fundamental importance, orchestrating organismal development, tissue homeostasis and immunity. Recently, powerful methods that use single-cell genomic technologies to dissect physically interacting cells have been developed. However, these approaches are characterized by low cellular throughput, long processing times and high costs and are typically restricted to predefined cell types. Here we introduce Interact-omics, a cytometry-based framework to accurately map cellular landscapes and cellular interactions across all immune cell types at ultra-high resolution and scale. We demonstrate the utility of our approach to study kinetics, mode of action and personalized response prediction of immunotherapies, and organism-wide shifts in cellular composition and cellular interaction dynamics following infection in vivo. Our scalable framework can be applied a posteriori to existing cytometry datasets or incorporated into newly designed cytometry-based studies to map cellular interactions with a broad range of applications from fundamental biology to applied biomedicine. Interact-omics, a high-throughput cytometry-based framework, resolves the cellular interaction landscape.
Fostering the Implementation of Liquid Biopsy in Clinical Practice: European Liquid Biopsy Society (ELBS) 2024 Meeting Report by Klaus Pantel et al. Journal of Experimental & Clinical Cancer Research Catherine Alix-Panabières
Proud to be part of the team that published this new #liquidbiopsy study! This study is the largest pooled analysis with globally collected individual patient…
Researchers developed a microfluidic platform using surface-enhanced Raman spectroscopy (SERS) to detect single pancreatic cancer cells. The platform successfully differentiated between cancer stages, offering a promising tool for early cancer diagnosis through molecular analysis of individual...
The scale of the plots presenting your flow cytometry data are actually critically important in getting good results with high dimensional data analysis. The…
Heterogeneous circulating tumor cells (CTCs) have been implicated in the formation of new metastases. However, circulating cells expressing both tumor and immune cell proteins are often dismissed as insignificant findings in CTC studies. Two non-contemporaneous blood samples from a metastatic breast cancer patient were analyzed using an enrichment-free platform to identify canonical, epithelial-only CTCs (CD45-/cytokeratin + , epi.CTCs) and CD45 + /cytokeratin+ immune-like CTCs (im.CTCs). Single cells from both samples were subjected to copy number and protein expression profiling. A cohort of 36 metastatic breast cancer patients was then analyzed to search for additional cases with im.CTCs. Here, we identified and characterized a population of CTCs exhibiting an immune-like state. In two samples from an index patient, im.CTCs outnumbered epi.CTCs, comprising >97% of the CTC population. Single-cell copy number analysis of 43 im.CTCs and 30 epi.CTCs revealed clonal alterations across both populations, confirming a shared tumor origin. Furthermore, im.CTCs contained pseudo-diploid profiles that did not reflect dilution from the addition of a normal diploid genome, indicating that they were unlikely to have originated from tumor-immune cell fusion. Protein expression analysis showed that im.CTCs express CD45 as well as other immune-related markers, such as CD3 and CD4, and the cancer stemness marker, CD44. Subsequent analysis of a metastatic breast cancer cohort identified an additional patient harboring im.CTCs with the same tumor-derived, non-fusion genome as in the index case. Collectively, these genomic and proteomic features distinguish im.CTCs from previously reported circulating cells may represent a novel form of tumor cell plasticity. Tumor cells are known to take on features that allow them to survive and move to new sites. This variation can make it difficult to distinguish them from other cells in the blood. Using a platform to profile rare cells in blood samples, we identified a population of cells expressing cancer and immune cell proteins in a breast cancer patient. Genomics data confirmed that these cells originated from the tumor and that they were different from another cell type sharing a similar protein expression pattern. We analyzed additional samples and found a second patient with these immune-like tumor cells. These findings support the existence of a cancer-immune state that might play a role in helping tumor cells spread. Higa et al. analyzed circulating cells expressing cancer and immune cell markers in breast cancer patients. Based on genomic and protein expression profiling, they show that the cells were unlike previously described circulating tumor cells with immune-like phenotypes because they did not appear to arise from heterotypical cell fusion.
💫 Super excited to share our latest review just published in Nature Portfolio.
Liquid biopsies🩸, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring. Circulating tumour DNA (#ctDNA) 🧬 and circulating tumour cells (#CTCs) are promising blood-based biomarkers in bladder cancer. Results from several studies have shown the clinical potential of ctDNA and CTCs in #bladder #cancer for prognostication, treatment-response monitoring, and early detection of minimal residual disease (#MRD) and disease recurrence. Following successful clinical trial evaluation, assessment of ctDNA and CTCs holds the potential to transform the therapeutic pathway for patients with bladder cancer — potentially in combination with the analysis of urinary tumour DNA — through tailored treatment guidance and optimized disease surveillance.
👏👏👏 Sia Viborg Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew Galsky, Tom Powles, Mads Agerbæk, Jørgen Bjerggaard Jensen, Catherine Alix-Panabières & Lars Dyrskjøt
🤩 Good reading !
CHU de Montpellier, Recherche et innovation – CHU de Montpellier, Renan Targhetta, Samir JABER Liquid Biopsy LCCRH Lab - Laboratoire Cellules Circulantes Rares Humaines 🩸 Aarhus University European Liquid Biopsy Society (ELBS) PANCAID, GUIDE.MRD OncoDaily | 11 comments on LinkedIn
Le score de Matutes, décrit par le Dr Matutes du Royal Marsden Hospital à Londres en 1994, est un score diagnostique de la leucémie lymphoïde chronique (LLC), la forme la plus fréquente de leucémie chronique chez l'adulte. Il est basé sur l'étude de l’expression, par cytomérie en flux, de 5 marqueurs de surface des lymphocytes B: le CD5, le CD23, le FMC7, le CD79b et l'intensité de l'immunoglobuline de surface. Un point est ou non attribué en fonction de l’expression de chaque marqueur, et un score supérieur ou égal à 4 est très en faveur du diagnostic de LLC. Dans les combinaisons d’anticorps utilisées en cytométrie en flux pour le diagnostic des hémopathies lymphoïdes B, est systématiquement présent le CD20 qui permet d'isoler la population B, c’est également une cible thérapeutique. L’anticorps anti FMC7 reconnaissant un épitope de la protéine CD20, il y a compétition entre les anticorps et l’étude du FMC7 nécessite donc un tube spécifique, actuellement en 8 couleurs/8 antigènes.
Les cytomètres de routine hospitalière passant de 8-10 couleurs à 12-13 couleurs, Valérie Bardet et ses collaborateurs de du Service d'Hématologie-Immunologie-Transfusion des Hôpitaux Universitaires Paris Ile de France-Ouest (UVSQ/UPSaclay, Boulogne-Billancourt) se sont demandés s'ils pouvaient remplacer l’étude du FMC7 par celle de l’intensité du CD20, ceci afin de limiter le nombre d’anticorps utilisés et donc le coût et le temps des techniques. Leur étude parue dans le British Journal of Haematology a été réalisée sur une cohorte de 508 patients atteints d’hémopathie lymphoïde B chronique provenant des hôpitaux Ambroise Paré et Saint Louis. Elle a permis de montrer qu’une nouvelle modalité de calcul était possible avec des performances égales au score historiquement décrit.
Légende Figure : Comparaison des résultats du calcul du score avec le FMC7 (barre de gauche) ou le CD20 (barre de droite) dans différents types d'hémopathies B (CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B‐cell lymphoma; FL, follicular lymphoma; HCL, hairy cell leukaemia; MCL, Mantle cell lymphoma; MZL, marginal zone lymphoma; SDRPL, splenic diffuse red pulp small B‐cell lymphoma; WM, Waldenström macroglobulinaemia)
Speaker Biography: Jordi Petriz received his BSc degree in Biochemistry and Animal Biology from the University of Barcelona. He then pursued his PhD at Barcelona after acceptance at the Cryobiology and Cell Therapy Department, Cancer Research Institute (IRO)...
Webinar: Flow cytometry as you have never seen it before
Webinar Abstract: The Invitrogen™ Attune™ CytPix Flow Cytometer can simultaneously collect fluorescence data and high-resolution brightfield images of individual cells. This allows to better understand the morphology of each cell population identified for analysis. The images can be used to study cell-cell interactions, rare event identification, and rapid confirmation of disease...
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
![Single-cell mass cytometry of differential immune an... [Science. 2011] - PubMed - NCBI | from Flow Cytometry to Cytomics | Scoop.it](https://img.scoop.it/R49xnLrZXb91oy4sAbghFTl72eJkfbmt4t8yenImKBVvK0kTmF0xjctABnaLJIm9)
Scoop.it!
Your new post is loading...
Flow cytometry is an essential tool for dissecting the functional complexity of hematopoiesis. We used single-cell "mass cytometry" to examine healthy human bone marrow, measuring 34 parameters simultaneously in single cells (binding of 31 antibodies, viability, DNA content, and relative cell size). The signaling behavior of cell subsets spanning a defined hematopoietic hierarchy was monitored with 18 simultaneous markers of functional signaling states perturbed by a set of ex vivo stimuli and inhibitors. The data set allowed for an algorithmically driven assembly of related cell types defined by surface antigen expression, providing a superimposable map of cell signaling responses in combination with drug inhibition. Visualized in this manner, the analysis revealed previously unappreciated instances of both precise signaling responses that were bounded within conventionally defined cell subsets and more continuous phosphorylation responses that crossed cell population boundaries in unexpected manners yet tracked closely with cellular phenotype. Collectively, such single-cell analyses provide system-wide views of immune signaling in healthy human hematopoiesis, against which drug action and disease can be compared for mechanistic studies and pharmacologic intervention.